Human plasma-mediated hypoxic activation of indolequinone-based naloxone pro-drugs.

[1]  D. Bloodworth.  Opioids in the treatment of chronic pain: legal framework and therapeutic indications and limitations. , 2006, Physical medicine and rehabilitation clinics of North America.

[2]  J. Conklin,et al.  Intestinal Motility During Hypoxia and Reoxygenation in Vitro , 1997, Digestive Diseases and Sciences.

[3]  D. Naughton,et al.  1H NMR studies on the reductively triggered release of heterocyclic and steroid drugs from 4,7-dioxoindole-3-methyl prodrugs , 2003 .

[4]  R. Borch,et al.  Studies on the mechanisms of activation of indolequinone phosphoramidate prodrugs. , 2003, Journal of medicinal chemistry.

[5]  R. Borch,et al.  Design, synthesis, and biological evaluation of indolequinone phosphoramidate prodrugs targeted to DT-diaphorase. , 2002, Journal of medicinal chemistry.

[6]  B. Vojnovic,et al.  Modifying rates of reductive elimination of leaving groups from indolequinone prodrugs: a key factor in controlling hypoxia-selective drug release. , 2002, Biochemical pharmacology.

[7]  C. Moody,et al.  Indolequinone antitumor agents: correlation between quinone structure and rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase. Part 2. , 2001, Journal of medicinal chemistry.

[8]  D Zuder,et al.  Current therapies for wound healing: electrical stimulation, biological therapeutics, and the potential for gene therapy , 1999, International journal of dermatology.

[9]  I. Stratford,et al.  Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships. , 1999, Journal of medicinal chemistry.

[10]  C. Stevens,et al.  Influence of hypoxia in inflammatory synovitis , 1998, Annals of the rheumatic diseases.

[11]  P. Workman,et al.  Bioreductive drugs into the next millennium. , 1998, Anti-cancer drug design.

[12]  G. Adams,et al.  Indolequinone antitumor agents: reductive activation and elimination from (5-methoxy-1-methyl-4,7-dioxoindol-3-yl)methyl derivatives and hypoxia-selective cytotoxicity in vitro. , 1998, Journal of medicinal chemistry.

[13]  D. Ross,et al.  Indolequinone antitumor agents: relationship between quinone structure and rate of metabolism by recombinant human NQO1. , 1998, Bioorganic & medicinal chemistry letters.

[14]  J. Schmedtje,et al.  Hypoxia and molecular cardiovascular medicine. , 1998, Trends in cardiovascular medicine.

[15]  G. Adams,et al.  2-Cyclopropylindoloquinones and their analogues as bioreductively activated antitumor agents: structure-activity in vitro and efficacy in vivo. , 1997, Journal of medicinal chemistry.

[16]  C. Ikonomidou,et al.  Excitotoxicity and neurodegenerative diseases. , 1995, Current opinion in neurology.

[17]  J. Fishman,et al.  Narcotic antagonists. 1. Isomeric sulfate and acetate esters of naloxone (N-allylnoroxymorphone). , 1973, Journal of medicinal chemistry.

[18]  Lars Ernster.  [56] DT diaphorase , 1967 .